An Investigator-Initiated Research study of ZTLido in subjects with chronic non-radicular neck pain
Latest Information Update: 05 Nov 2024
At a glance
- Drugs Lidocaine (Primary)
- Indications Pain
- Focus Therapeutic Use
Most Recent Events
- 30 Oct 2024 According to a Scilex Holding media release, company announced that it had a successful end of Phase II meeting with the FDA leading to an agreed path forward to NDA upon completion of Phase III trials for blockbuster product candidate, SP-103 (lidocaine topical system) 5.4%, a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain associated with muscle spasms.
- 19 Dec 2023 Results were presented in a Scilex Holding Media Release.
- 20 Sep 2023 New trial record